Insider Selling: Teva Pharmaceutical Industries (NYSE:TEVA) Director Sells $4,822,000.00 in Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Director Roberto Mignone sold 200,000 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $24.11, for a total value of $4,822,000.00. Following the completion of the transaction, the director directly owned 495,000 shares in the company, valued at approximately $11,934,450. This represents a 28.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Teva Pharmaceutical Industries Stock Up 2.6%

TEVA opened at $25.78 on Thursday. The business has a 50 day moving average of $20.12 and a 200-day moving average of $18.08. The stock has a market capitalization of $29.56 billion, a price-to-earnings ratio of -161.10, a P/E/G ratio of 1.11 and a beta of 0.70. The company has a current ratio of 1.06, a quick ratio of 0.77 and a debt-to-equity ratio of 2.45. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $25.88.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, November 5th. The company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.10. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The business had revenue of $4.48 billion for the quarter, compared to analyst estimates of $4.36 billion. During the same quarter in the previous year, the firm posted $0.69 earnings per share. Teva Pharmaceutical Industries’s revenue was up 3.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.550-2.650 EPS. As a group, sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Bourgeon Capital Management LLC boosted its stake in Teva Pharmaceutical Industries by 100.7% in the second quarter. Bourgeon Capital Management LLC now owns 723,974 shares of the company’s stock valued at $12,134,000 after acquiring an additional 363,252 shares during the last quarter. Amundi raised its position in shares of Teva Pharmaceutical Industries by 18.5% during the 1st quarter. Amundi now owns 678,758 shares of the company’s stock valued at $10,080,000 after acquiring an additional 105,846 shares during the last quarter. IFM Investors Pty Ltd lifted its stake in shares of Teva Pharmaceutical Industries by 9.4% in the 2nd quarter. IFM Investors Pty Ltd now owns 226,534 shares of the company’s stock valued at $3,797,000 after purchasing an additional 19,447 shares during the period. Jump Financial LLC boosted its position in shares of Teva Pharmaceutical Industries by 172.1% in the 1st quarter. Jump Financial LLC now owns 1,325,526 shares of the company’s stock worth $20,373,000 after purchasing an additional 838,423 shares during the last quarter. Finally, Financial Sense Advisors Inc. boosted its position in shares of Teva Pharmaceutical Industries by 63.5% in the 1st quarter. Financial Sense Advisors Inc. now owns 405,421 shares of the company’s stock worth $6,231,000 after purchasing an additional 157,421 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on TEVA. UBS Group increased their target price on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. raised their target price on Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $25.86.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.